Vanda Pharmaceuticals reports USPTO notice of patent allowance Vanda Pharmaceuticals disclosed in a regulatory filing that on June 10 the company received a notice of allowance from the United States Patent and Trademark Office for a patent covering the method of use of HETLIOZ to treat Non-24-Hour Sleep-Wake Disorder. The allowed claims relate to the method of treatment as described in the HETLIOZ label that was approved by the FDA and include claims directed to treatment of the totally blind population that has this disorder. Following the expected issuance of the VAND-0092 patent, Vanda intends to submit the patent for listing in the FDA publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The VAND-0092 patent, when issued, would be expected to expire in 2033, thereby potentially extending the exclusivity protection in the U.S. for method of using HETLIOZ in Non-24 beyond the expiration of the U.S. composition of matter patent for HETLIOZ, which is currently expected to expire in 2022.
News For VNDA From The Last 14 Days
Check below for free stories on VNDA the last two weeks.